Cargando…
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
In acute myeloid leukemia (AML), risk stratification based on cytogenetics and mutation profiling is essential but remains insufficient to select the optimal therapy. Accurate biomarkers are needed to improve prognostic assessment. We analyzed RNA sequencing and survival data of 430 AML patients and...
Autores principales: | Marquis, Miriam, Beaubois, Cyrielle, Lavallée, Vincent-Philippe, Abrahamowicz, Michal, Danieli, Coraline, Lemieux, Sébastien, Ahmad, Imran, Wei, Andrew, Ting, Stephen B., Fleming, Shaun, Schwarer, Anthony, Grimwade, David, Grey, William, Hills, Robert K., Vyas, Paresh, Russell, Nigel, Sauvageau, Guy, Hébert, Josée |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066481/ https://www.ncbi.nlm.nih.gov/pubmed/30061630 http://dx.doi.org/10.1038/s41408-018-0103-6 |
Ejemplares similares
-
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
por: Marquis, Miriam, et al.
Publicado: (2019) -
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting
por: Tremblay, Gabriel, et al.
Publicado: (2019) -
Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia
por: Lisi, Véronique, et al.
Publicado: (2022) -
Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets
por: Maiga, A, et al.
Publicado: (2016) -
HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
por: Moison, Céline, et al.
Publicado: (2022)